Quantcast

Latest Human Genome Sciences Stories

2009-04-29 15:05:00

- First HGS product sales achieved with delivery of ABthrax(TM) to U.S.

2009-04-25 09:00:00

- With half as many injections, in two pivotal Phase 3 trials, Albuferon (albinterferon alfa-2b) met the primary efficacy endpoint of sustained virologic response comparable to Pegasys (peginterferon alfa-2a) - - Patients receiving 900-mcg Albuferon had comparable rates of serious and/or severe adverse events across the two Phase 3 trials, versus peginterferon alfa-2a - - Submission of global marketing applications planned in fall 2009 - ROCKVILLE, Md., April 25 /PRNewswire-FirstCall/ --...

2009-04-22 15:00:00

ROCKVILLE, Md., April 22 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it will sponsor a conference call to discuss its financial results for the quarter ended March 31, 2009.

2009-03-27 07:00:00

ROCKVILLE, Md., March 27 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) announced today that its presentation at the 4th Annual Citi Biotech Day will be webcast and may be accessed at www.hgsi.com.

2009-03-25 06:16:00

ROCKVILLE, Md. and EXTON, Pa., March 25 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc.

2009-03-17 14:38:00

WASHINGTON, March 17 /PRNewswire/ -- The 3rd Annual Walk for Lupus Now Washington will occur on Saturday, April 18 from 9:00 a.m. to 12:00 noon on Pennsylvania Avenue, N.W. between 13th and 3rd Streets.

2009-03-13 07:00:00

ROCKVILLE, Md., March 13 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc.

2009-03-09 06:01:00

ROCKVILLE, Md., March 9 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc.

2009-03-09 06:00:00

- 900-mcg Albuferon (albinterferon alfa-2b) dosed every two weeks met the primary efficacy endpoint of sustained virologic response comparable to peginterferon alfa-2a dosed weekly in patients with genotype 1 chronic hepatitis C - - Patients receiving 900-mcg Albuferon had comparable rates of serious and/or severe adverse events versus peginterferon alfa-2a - - Filing of global marketing applications planned in fall 2009 - ROCKVILLE, Md., March 9 /PRNewswire-FirstCall/ -- Human Genome...

2009-02-26 15:11:00

- Positive results for first Albuferon(R) Phase 3 trial announced in December 2008; data from second trial expected March 2009 - - Phase 3 trials of darapladib for cardiovascular disease and Syncria(R) for type 2 diabetes initiated by GlaxoSmithKline (GSK) - - $106 million of convertible debt repurchased for $50 million in cash - - 2009 revenue expected to grow to $250 million; at least $150 million from delivery of ABthrax(TM) to Strategic National Stockpile - ROCKVILLE, Md., Feb.


Word of the Day
overword
  • To say in too many words; to express verbosely.
  • To express in too many words: sometimes used reflexively.
  • The leading idea or a repeated phrase, as of a song or ballad; the refrain; burden.
The word 'overword' comes from over- +‎ word.